Lakewood, Colorado, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, today announced the acquisition of substantially all of the assets (other than current assets) and certain liabilities related to Belyntic GmbH’s (“Belyntic”) peptide purification business. The transaction price and near-term financial impact are not material to Mesa’s ongoing operations.
“The acquisition of Belyntic’s peptide purification products provide Mesa with a natural complement to our peptide synthesis business by adding an advantaged consumables product line. The combination will enhance Mesa’s focus on the biopharmaceutical market to support faster therapeutic development.” said Gary Owens, President and Chief Executive Officer of Mesa. “Belyntic has developed a best-in-class solution for the parallel purification and modification of difficult peptides. Their Peptide Easy Clean (“PEC”) Linker represents the first broadly applicable peptide purification kit that utilizes catch-and-release methodologies, drastically reducing the need for organic solvents, improving the ecological impact.”
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," “will”, “estimate,” "expect," "project," “anticipate,” “intend” and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenues growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2022, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.
CONTACT: Gary Owens.; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000 For more information about the Company, please visit its website at www.mesalabs.com
